Targeting the dysregulated lipid metabolism in cancer through the inhibition of transporters CD36 and FABP4, the disruption of de novo lipogenesis, and FAO enzymes, as well as cholesterol synthesis, has revealed potential avenues for therapeutics. The gene discussed is FABP4; the disease is cancer.